Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice Volume & PPS Rise, Plenty Of News To Maintain Momentum, imo.
MMRF ON FIRE, RUNAWAY TRAIN . . IMO.
Provide a link!
EZ
Did you see BL and Kira on F&F this morning? 0420 their time! That's a working Son of a Gun! We're in goods hands..
I can't find the ticker symbol
MMRF: MIMV mobile apps have been in contact?
That is well known from a few months back and has been discussed in various forums.
Nothing to do with MMRF!
Someone already shot himself in the foot we could be at .20 sooner that you think fundamentals are now greater than they ever were hopefully you got in at .0111......MMRF Presently .1165 up 16.50%
MMRF: In talks mobile apps partner MIMV moving now.
Looking very strong for both this morning.
perhaps news brewing.
Anyone care to comment
imo good sign with bid following the ask up. Maybe no retrace at all.
MMRGlobal Patent Valuation Increases From Issuance of Japanese Patent
Monday 6 May 2013
MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs) MyEsafeDepositBox storage solutions and MMRPro document management and imaging systems for healthcare professionals, is featured in an updated valuation report following the issuance by the Japan Patent Office of Patent No. 5191895 entitled a "Method and System for Providing Online Medical Records." The Japanese patent, issued on February 8, 2013, increases the valuation by the Michael Bass Research Group by $200 million, from an initial report of $600 million to $1.1 billion, to $800 million to $1.3 billion. The report can be seen at http://michaelbass.com/PDF/Patent_Valuation.pdf. The Japanese patent includes 40 claims relating to accessing health records through a Web site, collecting health records directly from healthcare providers, and managing the records such as by organizing the documents, applying additional password protection, and electronically sending the health records to healthcare providers. The patent is specifically relevant to the market at this time following the launch of the country's "My Hospital Everywhere" Japan Personal Health Record service concept. Additional patent applications are also pending in Japan.
The "My Hospital Everywhere" program is designed to help enable individuals in Japan to receive their own medical and health-related information from medical institutions and to maintain and manage it electronically, which is a significant part of MMR's patented technologies. The implementation of Electronic Medical Records in Japan is a high priority as a result of findings from the aftermath of the March 11, 2011 earthquake and tsunami. The medical system in Japan was overwhelmed with thousands of people in hospitals and doctors' offices with no medical records. As a result, thousands unnecessarily lost their lives, and the cost of care without having information about the patient was significantly increased, making deployment of "My Hospital Everywhere" a national priority.
The value of the Company's patents in Japan is underscored by an interview with Dr. Makoto Aoki in The National Bureau of Asian Research on June 2, 2011. Dr. Aoki, Scientific Executive at Sakura Seiki Co. Ltd., a Japanese company that specializes in the design and manufacturing of medical and laboratory equipment, and a Member of the American College of Physicians, said, "Physicians have had a hard time identifying patients' medications since patients often remember their medications only by their shape or color. Most of the hospitals that patients had attended also lost their medical records as a result of the earthquake or tsunami." MMR's PHR systems include the ability to track and manage a patient's medication data base.
MMR has seven issued U.S. patents as well as additional applications and continuation applications with nearly 400 claims relating to Personal Health Records transmitted via an Internet portal under the heading of "Method and System for Providing Online Medical Records" and "Method and System for Providing Online Records." MMR's patent portfolio also includes numerous other issued patents and pending applications in countries of commercial interest around the world which, in addition to Japan, include Australia, Singapore, New Zealand, Mexico, Canada, Hong Kong, South Korea, Israel, and European nations.
The report by the Michael Bass Research Group also includes the earlier report presenting a comprehensive overview of the U.S. Personal Health Records market, with particular emphasis on MMRGlobal's MyMedicalRecords Health Information Technology Global Patent portfolio. This report includes schedules of the Company's domestic and international MMR patent portfolios, a valuation analysis and summary of conclusions.
The Company's patents also contain claims directed to Web-based services that provide access to and collect health records from service providers, including, but not limited to, retail pharmacies and laboratory systems as well as hospitals, physicians and other healthcare professionals, using email, facsimile, file upload and voice. Certain claims in newly allowed applications also relate to collecting insurance information, appointment and medication reminders and other features that are already included in MMR's MyMedicalRecords.com PHR.
About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.
About The Michael Bass Group:
The Michael Bass Group (MBG) (http://michaelbass.com) is an investment banking and strategic advisory services firm focused on healthcare information technology, healthcare IT services, and mobility providers as well as medical devices. MBG tracks and conducts research on over 400 emerging growth companies in the HIT sector. The Michael Bass Research Group also looks at economic, market, industry and company data relevant to the healthcare sector.
Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, whether or not such statement relates directly to the Michael Bass Research Group valuation reports, and including, without limitation, intellectual property licenses, property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry both in the U.S. and internationally; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission, including disclosures about the Company's relationship with the Michael Bass Group since 2009. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
CONTACT:
Michael Selsman
Public Communications Co.
ms@publiccommunications.biz
(310) 922-7033
Jagman... near .20 : 2009 and also in 2010
What a POC....wasn't this 10 cents a couple of years ago?? And the "fundamentals" are much worse!! LMAO!!!
http://finance.yahoo.com/q/ks?s=MMRF+Key+Statistics
MMRF will put out info on the new BASS patent evaluation for Japan tomorrow!..per the CEO..
portcitybob.. according to yahoo finance os=552 million shares.
MMRGlobal, Inc. (MMRF)
MyMedicalRecords.com voice and fax communications portal was built and is hosted by the same company that handles transactions for many of the nation's major financial institutions and Fortune 1000 companies!!
From sources in the industry, if MMRGlobal acquires over $150 million in revenue this stock currently trading at $.03 could realistically trade at a valuation of $3.50 - $4.00 stock with a market cap in the $800mm to 1.2b range !!
https://www.mymedicalrecords.com/login.jsp
MMRF & mobile apps leader MIMV: Perfect together.
There was quite a bit made about the meeting between the CEOs of MMRF and mobile app developer Mimvi.
MMRFs strong move north is being mirrored by an early stage move by MIMV, as well.
My bet is that MMRF insiders are loading up on both right now.
Anyone care to comment.
https://play.google.com/store/apps/details?id=com.mimvi.appsearch&feature=search_result#?t=W251bGwsMSwyLDEsImNvbS5taW12aS5hcHBzZWFyY2giXQ..
Does anyone know what the outstanding share count is?
There is absolutely one thing I am sure of and that is there are going to be a bunch of millionaires on this board by the end of the year based purely on E-Mail Frequency revenues coming in all the future quarters starting in the 2nd this year and all thru next year and beyond. I was told that the 20 million embedded PHR's looks like it may be exceeded and as that was a forecast for an 18 month period starting in 2012 until the end of January 2014 then I can well expect the embedded business to really soar during 2014 and of course beyond worldwide. I hope everybody knows that sales are not only in the U.S. but worldwide. We will be looking at dollars next year and a different exchange where we will be in multi-dollars. A 2 for 1 reverse split may or may not happen depending on short term influx of revenue. Of course a buyout is the most likely scenario as I totally agree with Investbernie on that matter who is really a believer as we all are who also has multi- million shares..JMO...Tif
I think we still have a ways to move. Personally, I hope for it to settle down and base in this area before moving again. That may not be the case if significant news hinted by Bob last week comes out. Any news on a settlement of any one of the pending cases or something along those lines may throw a wrench into the baseing idea. Anyway, its anyone's guess what happens next. Up, down or sideways its all good in the longer run.
Short term as you seem to be I would say the PPS may well languish until revenues come in! If you were long term then I would say by end of year more like 40 cents on up!..JMO..Tif
WRONG (again)
Patent troll is a pejorative term used for a person or company that enforces its patents against one or more alleged infringers in a manner considered unduly aggressive or opportunistic, often with no intention to manufacture or market the product. A related, less pejorative expression is non-practicing entity (NPE) which describes a patent owner who does not manufacture or use the patented invention."
http://en.wikipedia.org/wiki/Patent_troll
If anyone believes this post contains anything false, tortious or libelous, please point it out. I will promptly retract it and apologize or else explain why I believe you are wrong.
Not surprising Walgreens wants to litigate this
A settlement only encourages more patent trolls to file suit. MMRF opened up Pandora's box by suing 3 deep pocketed defendants. none will settle and the suits will only discourage any license payments at all
there are plenty of what?
Most references I see for the Bass group are from MMRF PR's. It looks like a twentysomething guy who does these reports on the side and not as his primary occupation.
The only point I can think of is that I should never post after driving for 12 hours. LOL!
And your point is?
.20 possible next week? Anyone?
Quote from website;The MichaelBass Group always begins an engagement with a comprehensive analysis of a client's long-term objectives. We then apply our in-depth industry experience and broad technical skill to identify the creative solutions and financing options that will deliver long-term value and assist clients in effectively implementing their strategic business and capital plans. MBG also hosts two, annual Health Technology Investment Forum's with the Institute for Health Technology Transformation taking place in New York City and San Francisco.END....I think they are probably doing well with a bunch of clients if they are hosting these 2 annual events each year. They do have a phone number and perhaps calling them and telling them if they listed their past/present accounts on their website it would sure be positive input/references for their business. I might call them and ask "Why Not?"..JMO..Tif
Are their reports worth their weight in gold? We all know how reports can be, well, just reports. Heck, I can issue a report, but I wouldn't take stock in it if i wrote it. So, how reputable are those who wrote the report? I know, do my own DD...
Thank you for your insight and I really do not believe in luck but more like an educated "guess". I guess this company will do very well due to embedded PHR's, Australia, China, Patent infringement cases, Celgene pay out, possible more Bio non-exclusive contracts, Japan, England, Current U.S. contracts already signed, New UNIS/MMRF joint venture with a product that will talk to all EMR's in the world and bring in what I believe to be the whole package for any medical facility to want and need, Bob Lorsch's involvement with the Emir who wants medical records in his country, and on and on. So I guess I will just keep on my educated guessing!...and good guess to you too..later, Tif
scroll down here michaelbass.com/PDF/Patent_Valuation.pdf or Try to Google them....there are plenty!
Thank you Mark.....Why are some so ???????
I'm interested in seeing what the Bass group has valued other companies patents at.
They have published reports on other companies haven't they? Or is MMRF their only paying customer?
Financial Reports Always Have Cautionary Statements Just To Cover Their Ass_ets, imo.
DOCTOR AFRIDI Help Bob Lorsch make USA do the right thing. This is good publicity for MMR too!
Listen to Frank Gaffney's Secure Freedom Radio interview BOB did last week on the plight of Dr. Afridi. Then watch Kira & BOB on Fox & Friends Monday May 8th in the 7:00 AM hour.They will certainly be the smartest ones on the show! ))))
[url]
www.centerforsecuritypolicy.org/2013/05/02/from-hollywood-to-washington-a-quest-to-free-dr-afrid[/url][tag]insert-text-here[/tag]
tiffer ol' friend, I think you should reread that report. It says the Japanese patents could add $200 million to the total valuation number, not $800 million to over a billion. But more important, don't dismiss this part:
Alright, A Billion Dollars In Patents, That Explains The PPS Rise, Let The Word Spread Far And Wide, Headed To A Dollar, imo.
Or is this why it hit 10? Pay attention to the date it came out. "Kids say the darnedest things!"...At Linkletter..
Excellent update: Our initial valuation of the patent portfolio in our report dated January 22, 2013 http://michaelbass.com/PDF/
Patent_Valuation.pdf was a range of $600 million to $1.1 billion. Based on our analysis, and the issuance of the patent
in Japan being added to the patent portfolio, the range of value for these patents could reach $800 million to $1.3
billion USD in revenue based on very conservative estimates. This assumes the market will reach the full GDP value of
$19 billion USD in the next 10 years in the United States and $5 billion USD in value in the next 10 years in Japan. This
valuation does not take into account changes or risks associated with foreign currency rates. The risk factors for these
patent values not realizing their predicted range of value include, adoption rate of PHRs, the claims granted in the
patents are not enforceable and widely used, the market doesn’t grow as quickly as predicted, the prices for PHRs
drop substantially, and or government/regulatory forces. This valuation does not take into account the international
patents pending which have not yet issued in the patent portfolio. This valuation does not include the patents issued in
Mexico, Australia, Singapore, and New Zealand.
Nick, Were you acting as private counsel to Walgreens. Almost all of the statements in their official response to the court about the MMRF Lawsuit said that they Know Nuttin about those pesky patents. Sounded suspiciously like your alias to me. lol And, those funds in the "health care" company from the other company were already readirected. :>}
Nice report. It was dated May 2nd, so I think some may have had their eyes on it early and it was the reason for the high volume we got. I know some of the daytraders also contributed to that high volume but I don't believe its over by a long shot. Once that report is out I think it will help draw more eyes on the company and its long range business plans which are just now starting to take root.
Having all those international patents is great, and now that it appears that the U.S. patents may actually be tested it will bring even more attention to what the company has going on. I think its a win win along with those Revenues that RHL and EMF are putting together its going to capture quite an audience in the not too distant future.
MMRF: Wait till the report hits to the masses! And up we go BIG!!!
http://michaelbass.com/PDF/Patent_Valuation.pdf
Thanks and WOW is this Big....Perhaps we may still hit a dollar PPS this year..The Bass group values our Japanese patent between 800 million to over a billion for the Jampanese market that needs our PHR. A FIVE Billion revenue stream over the next 10 years for 130 million Japanese citizens! They are going to love our new MMRF/UNIS combination unit of the EMR/PHR...WOWSEERRRRR!..Thanks again...Tif..http://michaelbass.com/PDF/Patent_Valuation.pdf
MMRF new Valuation Report 05/02/2013.. This is HUGE folks...
http://michaelbass.com/PDF/Patent_Valuation.pdf
Followers
|
311
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
77519
|
Created
|
05/27/08
|
Type
|
Free
|
Moderators |
Market Value1 | $6,819,661 | a/o Jun 17, 2015 | |
Authorized Shares | 1,250,000,000 | a/o Jul 17, 2013 | |
Outstanding Shares | 863,248,276 | a/o May 22, 2015 DISCLAIMER: |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |